Skip to main content

Table 5 Univariable survival analysis of immune metagenes stratified by subtype and proliferation tertile.

From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis

Subtype

PL

PI

PH

 

HR (95%CI)

P -value2

HR (95%CI)

P -value

HR (95%CI)

P -value

ER-

n = 51 3

n = 101

n = 249

B/P (L, I, H)1:

0.81 (0.33 to 2.00)

0.65

0.60 (0.41 to 0.89)

0.01

0.63 (0.48 to 0.83)

0.001

T/NK (L, I, H):

3.67 (1.13 to 11.9)

0.01

0.54 (0.38 to 0.78)

0.001

0.59 (0.44 to 0.78)

0.0003

M/D (L, I, H):

3.90 (1.28 to 11.9)

0.003

0.65 (0.45 to 0.94)

0.02

0.59 (0.45 to 0.78)

0.0002

ER+

n = 542

n = 458

n = 343

B/P (L, I, H):

0.77 (0.56 to 1.04)

0.09

1.03 (0.81 to 1.30)

0.83

0.56 (0.45 to 0.69)

< 0.0001

T/NK (L, I, H):

0.80 (0.59 to 1.10)

0.17

0.98 (0.78 to 1.23)

0.85

0.60 (0.48 to 0.73)

< 0.0001

M/D (L, I, H):

0.86 (0.64 to 1.16)

0.33

0.93 (0.74 to 1.18)

0.57

0.59 (0.48 to 0.73)

< 0.0001

Basal-like

n = 40

n = 113

n = 307

B/P (L, I, H):

0.97 (0.47 to 2.02)

0.94

0.64 (0.43 to 0.96)

0.03

0.67 (0.52 to 0.85)

0.001

T/NK (L, I, H):

1.63 (0.68 to 3.95)

0.23

0.48 (0.33 to 0.69)

0.0002

0.65 (0.51 to 0.83)

0.0006

M/D (L, I, H):

1.87 (0.74 to 4.72)

0.14

0.54 (0.37 to 0.79)

0.002

0.60 (0.47 to 0.77)

< 0.0001

HER2-E

n = 14

n = 66

n = 94

B/P (L, I, H):

0.70 (0.17 to 2.85)

0.62

0.72 (0.46 to 1.14)

0.16

0.51 (0.34 to 0.78)

0.002

T/NK (L, I, H):

0.08 (0.007 to 0.9)

0.02

0.79 (0.53 to 1.16)

0.23

0.46 (0.31 to 0.68)

0.0001

M/D (L, I, H):

0.66 (0.24 to 1.85)

0.43

0.96 (0.64 to 1.46)

0.86

0.53 (0.36 to 0.78)

0.001

Luminal B

n = 26

n = 135

n = 212

B/P (L, I, H):

2.28 (0.82 to 6.32)

0.11

0.97 (0.65 to 1.43)

0.86

0.52 (0.38 to 0.71)

< 0.0001

T/NK (L, I, H):

2.81 (1.06 to 7.49)

0.03

0.68 (0.43 to 1.08)

0.09

0.60 (0.45 to 0.80)

0.0002

M/D (L, I, H):

2.23 (0.83 to 5.96)

0.11

0.50 (0.30 to 0.83)

0.003

0.57 (0.42 to 0.77)

< 0.0001

Luminal A

n = 347

n = 200

n = 20

B/P (L, I, H):

0.71 (0.44 to 1.13)

0.14

0.95 (0.58 to 1.56)

0.83

1.41 (0.52 to 3.86)

0.50

T/NK (L, I, H):

0.57 (0.33 to 0.97)

0.03

1.08 (0.68 to 1.72)

0.73

0.98 (0.34 to 2.79)

0.96

M/D (L, I, H):

0.70 (0.44 to 1.12)

0.13

1.10 (0.71 to 1.71)

0.66

1.45 (0.44 to 4.79)

0.55

Claudin-Low

n = 31

n = 22

n = 39

B/P (L, I, H):

2.1 (0.53 to 8.00)

0.24

1.5 (0.59 to 3.79)

0.38

1.06 (0.56 to 2.03)

0.85

T/NK (L, I, H):

> 100 (0.00 to +inf)

0.02

0.70 (0.28 to 1.74)

0.45

0.87 (0.44 to 1.73)

0.69

M/D (L, I, H):

> 100 (0.00 to +inf)

0.05

0.63 (0.24 to 1.63)

0.36

0.78 (0.43 to 1.44)

0.44

  1. 1metagene tertiles (L: low; I: intermediate; H: high); 2likelihood ratio test P-value; 3number of cases in specified subtype and proliferation tertile. CI: confidence interval; ER: estrogen receptor-positive breast cancer; HER2-E: human epidermal growth factor receptor 2-enriched; HR: hazard ratio.